Biosimilar switching not suitable in some patients

Switching from infliximab to its biosimilar may lead to a loss of response and an increased risk of side effects in patients who develop antibody immunity, Spanish researchers say.

Their study of 250 patients with either rheumatoid arthritis or spondyloarthritis and 77 control patients shows around half tested positive for anti-infliximab antibodies.

All patients who tested positive for anti-infliximab antibodies had